TR

Trulieve Cannabis Corp.

TRLVHealthcareNASDAQ

Drug Manufacturers - Specialty & Generic · Last scanned Sep 4, 2026

PriceMA150MA200
Loading chart…
End-of-day data · ScananceOpen live chart on TradingView ↗
Indicator snapshot
MA150+45.33%
$8.25

Price above medium-term moving average.

MA200+48.94%
$8.05

Above long-term trend line.

RSI-14overbought
77.7

Above 70, may be overbought.

MACDpositive
+0.1261

Histogram positive, upward momentum.

Financials · Annual
Revenue
$1.18B
-0.4% YoY
Net Income
-$116.4M
+25.0% YoY
EBITDA
$328.3M
+21.0% YoY
Free Cash Flow
$232.0M

Scan Results

Daily timeframe

1 of 4 indicators bearish as of Sep 3

1 recent day hidden. Fresh signals are a Premium featureUpgrade →
DateIndicatorDetails
Sep 3 RSI OverboughtRSI 76.3, above 70, stock may be overbought
Sep 2 RSI OverboughtRSI 79.8, above 70, stock may be overbought
About Trulieve Cannabis Corp.

Trulieve Cannabis Corp. operates as a cannabis retailer in the United States. The company carries a $2.31B market cap, placing it firmly in the mid-cap category. The company cultivates, processes, and manufactures cannabis products and distributes its products to its dispensaries, as well as through home delivery.

Where TRLV stands vs its 150-day and 200-day moving averages

As of the September 3, 2026 close, TRLV finished 42.21% above its 150-day moving average ($8.22) and 45.76% above its 200-day moving average ($8.02). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.

Is TRLV overbought or oversold?

At the September 3, 2026 close, TRLV's RSI(14) was 76.3, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.

Key stats
Market Cap$2.31B
Fwd P/E21.58
EPS$-2.50
Beta1.72
52W Change+54.2%
ROE-47.6%
Analysis

Trulieve Cannabis Corp. carries $577.9M in total debt against $325.4M in cash reserves — debt is roughly 1.8x the cash position. Managing this leverage effectively will be important for long-term financial stability. Annual free cash flow of $232.0M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Return on equity stands at -47.6%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. ROA of 3.3% is on the lower side, which is common in asset-heavy industries. Revenue has been relatively flat, moving from $1.22B (2022) to $1.18B (2025).

A beta of 1.72 means TRLV is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Trulieve Cannabis Corp. and its sector.

Links
More Healthcare stocks
Browse all stocks →
Not financial advice. Scanance shows end-of-day technical indicators (not real-time prices) for information only. Results can be wrong; past performance does not guarantee future results.PrivacyTerms